MESOBLAST LTD.

Company Overview

Mesoblast Ltd. is a developer of innovative biological products for the broad field of regenerative medicine. The company’s commercial strategy is based on its unique, proprietary adult mesenchymal precursor cells known as mesenchymal lineage adult stem cells (MLCs). The company’s lead products target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions. Mesoblast and Cephalon Inc., a global biopharmaceutical company, have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.

The company’s off-the-shelf products are allogeneic, meaning cells from one donor may be used in many different recipients without the need for matching.

JCR Pharmaceuticals Co. Ltd., its licensee in Japan, has received full approval for the first allogeneic cell-based product in Japan based on MLC technology. In February 2016, it launched TEMCELL HS Inj., its mesenchymal stem cell product, for the treatment of acute graft-versus-host disease (aGVHD) in children and adults in Japan. TEMCELL is the first allogeneic cell therapy to be fully approved in Japan.

Lead product candidates currently under investigation include:

• MPC-06-ID for chronic low back pain due to disc degeneration.
• MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy.
• Remestemcel-L for inflammatory diseases in children and adults including the treatment of acute graft versus host disease (aGVHD).
• Revascor, which is in phase 3 for treatment for both advanced and end-stage chronic heart failure (CHF).

Financial Highlights (FY 2024)

Company's Business Segments

• Products : Products for Cardiovascular Diseases, Spine Orthopedic Disorders, Oncology and Hematology, Immune-Mediated and Inflammatory Conditions, Clinical Trials, Others